Newamsterdam Pharma CO N.V. (NAMSW) — SEC Filings

Q: What are the key financial highlights for Newamsterdam Pharma CO N.V.?

Key financial highlights for Newamsterdam Pharma CO N.V. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Newamsterdam Pharma CO N.V.?

Key executives at Newamsterdam Pharma CO N.V. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Newamsterdam Pharma CO N.V. stock?

Risk factors for Newamsterdam Pharma CO N.V. (NAMSW) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Newamsterdam Pharma CO N.V.?

Forward-looking statements and predictions from Newamsterdam Pharma CO N.V. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Newamsterdam Pharma CO N.V.. Recent 10-Q filing on Nov 5, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Newamsterdam Pharma CO N.V. on SEC EDGAR

Overview

Newamsterdam Pharma CO N.V. (NAMSW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: NewAmsterdam Pharma Co N.V. (NAMSW) reported a significant increase in net loss for the three months ended September 30, 2025, reaching $72.005 million, up from $16.647 million in the prior year, primarily driven by a substantial fair value change in warrants. Revenue for the quarter plummeted to $0

Sentiment Summary

Across 48 filings, the sentiment breakdown is: 2 bearish, 46 neutral. The dominant filing sentiment for Newamsterdam Pharma CO N.V. is neutral.

Filing Type Overview

Newamsterdam Pharma CO N.V. (NAMSW) has filed 6 10-Q, 30 8-K, 2 DEF 14A, 4 SC 13D/A, 4 SC 13G/A, 1 20-F/A, 1 10-K with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (48)

NewAmsterdam Pharma's Q3 Loss Widens on Warrant Valuation Swings — 10-Q · Nov 5, 2025 Risk: high
NewAmsterdam Pharma Co N.V. (NAMSW) reported a significant increase in net loss for the three months ended September 30, 2025, reaching $72.005 million, up from
NewAmsterdam Pharma Files 8-K — 8-K · Sep 2, 2025 Risk: low
NewAmsterdam Pharma Co N.V. filed an 8-K on September 2, 2025, reporting on events related to Regulation FD disclosure and financial statements. The filing conf
NewAmsterdam Pharma Files 8-K — 8-K · Aug 18, 2025 Risk: low
On August 18, 2025, NewAmsterdam Pharma Company N.V. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, along with Fi
NewAmsterdam Pharma Enters Material Definitive Agreement — 8-K · Aug 15, 2025 Risk: medium
On August 12, 2025, NewAmsterdam Pharma Company N.V. entered into a material definitive agreement. The filing also includes financial statements and exhibits re
NewAmsterdam Pharma's Q2 Loss Widens Amid R&D Surge — 10-Q · Aug 6, 2025 Risk: high
NewAmsterdam Pharma Co N.V. reported a net loss of $36.7 million for the three months ended June 30, 2025, an increase from a net loss of $28.5 million in the p
NewAmsterdam Pharma Files 8-K on July 30, 2025 — 8-K · Jul 30, 2025 Risk: low
NewAmsterdam Pharma Co N.V. filed an 8-K on July 30, 2025, reporting on various events. The filing includes information related to common stock and warrants, wi
NewAmsterdam Pharma Files 8-K on Officer/Director Changes — 8-K · Jul 11, 2025 Risk: low
On July 11, 2025, NewAmsterdam Pharma Co N.V. filed an 8-K report detailing the departure of directors or certain officers, the election of directors, and the a
8-K Filing — 8-K · Jun 11, 2025
NewAmsterdam Pharma Files 8-K — 8-K · Jun 9, 2025 Risk: low
On June 9, 2025, NewAmsterdam Pharma Company N.V. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events
NewAmsterdam Pharma Files 8-K on Shareholder Votes & Financials — 8-K · Jun 6, 2025 Risk: low
NewAmsterdam Pharma Co N.V. filed an 8-K on June 6, 2025, reporting on matters submitted to a vote of security holders and financial statements as of June 4, 20
NewAmsterdam Pharma Executive Compensation Details Released — DEF 14A · May 8, 2025 Risk: low
NewAmsterdam Pharma Co N.V. filed a DEF 14A on May 8, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes i
NewAmsterdam Pharma Q1 2025 10-Q Filed — 10-Q · May 8, 2025 Risk: medium
NewAmsterdam Pharma Co N.V. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance, including changes in fair value of ea
NewAmsterdam Pharma Files 8-K — 8-K · May 7, 2025 Risk: low
NewAmsterdam Pharma Co N.V. filed an 8-K on May 7, 2025, reporting on other events and financial statements. The filing details their corporate structure and pr
NewAmsterdam Pharma Reports Director/Officer Changes — 8-K · Apr 17, 2025 Risk: low
On April 15, 2025, NewAmsterdam Pharma Company N.V. filed an 8-K report detailing changes in its board of directors and officers, including the election of new
NewAmsterdam Pharma Files 8-K on Financials — 8-K · Feb 26, 2025 Risk: low
NewAmsterdam Pharma Co N.V. filed an 8-K on February 26, 2025, reporting on its results of operations and financial condition. The filing includes financial sta
NewAmsterdam Pharma Files 8-K — 8-K · Jan 10, 2025 Risk: low
On January 10, 2025, NewAmsterdam Pharma Company N.V. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and E
Frazier Life Sciences Amends 13D Filing for NewAmsterdam Pharma — SC 13D/A · Dec 17, 2024 Risk: medium
Frazier Life Sciences X, L.P. and its affiliates have filed an amendment to their Schedule 13D, reporting a change in beneficial ownership of NewAmsterdam Pharm
NewAmsterdam Pharma Enters Material Definitive Agreement — 8-K · Dec 13, 2024 Risk: medium
On December 11, 2024, NewAmsterdam Pharma Company N.V. entered into a material definitive agreement. The filing also includes Regulation FD disclosures and fina
NewAmsterdam Pharma Files 8-K — 8-K · Dec 10, 2024 Risk: low
NewAmsterdam Pharma Company N.V. filed an 8-K on December 10, 2024, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits.
NewAmsterdam Pharma Files 8-K — 8-K · Nov 20, 2024 Risk: low
On November 20, 2024, NewAmsterdam Pharma Co N.V. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events
NewAmsterdam Pharma Files 8-K — 8-K · Nov 18, 2024 Risk: low
NewAmsterdam Pharma Company N.V. filed an 8-K on November 18, 2024, reporting on various events. The filing includes information related to financial statements
Forbion Capital Partners Amends Stake in NewAmsterdam Pharma — SC 13D/A · Nov 15, 2024 Risk: medium
Forbion Capital Partners, through its affiliated entities Forbion Growth Management B.V., Forbion Growth Opportunities Fund I Cooperatief U.A., Forbion IV Manag
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
NewAmsterdam Pharma Q3 Update: Earnout & Warrant Valuation — 10-Q · Nov 6, 2024 Risk: medium
NewAmsterdam Pharma Co N.V. reported its third-quarter results for the period ending September 30, 2024. The company's filing details changes in the fair value
NewAmsterdam Pharma Files 20-F/A Amendment — 20-F/A · Oct 28, 2024 Risk: low
NewAmsterdam Pharma Co N.V. filed an amendment (20-F/A) on October 28, 2024, for its fiscal year ending December 31, 2022. The filing details its organizational
NewAmsterdam Pharma Restates Financials — 8-K · Oct 18, 2024 Risk: medium
NewAmsterdam Pharma Company N.V. announced on October 18, 2024, that it will not rely on previously issued financial statements or related audit reports. This d
SC 13G/A Filing — SC 13G/A · Aug 23, 2024
NewAmsterdam Pharma Files 8-K — 8-K · Aug 9, 2024 Risk: low
NewAmsterdam Pharma Co N.V. filed an 8-K on August 9, 2024, reporting other events and financial statements. The filing indicates the company's principal execut
NewAmsterdam Pharma Files Q2 2024 10-Q — 10-Q · Aug 7, 2024 Risk: medium
NewAmsterdam Pharma Co N.V. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance, including changes in the fair value of
NewAmsterdam Pharma Files 8-K — 8-K · Jul 29, 2024 Risk: low
On July 29, 2024, NewAmsterdam Pharma Company N.V. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events
NewAmsterdam Pharma Board Changes and Officer Compensation — 8-K · Jul 18, 2024 Risk: medium
NewAmsterdam Pharma Company N.V. announced on July 16, 2024, a change in its board of directors. Specifically, Dr. Jane Osipov has been appointed as a new direc
NewAmsterdam Pharma Files 8-K Report — 8-K · Jun 11, 2024 Risk: low
On June 11, 2024, NewAmsterdam Pharma Company N.V. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events
NewAmsterdam Pharma Files 8-K on Shareholder Votes & Exhibits — 8-K · Jun 7, 2024 Risk: low
On June 5, 2024, NewAmsterdam Pharma Company N.V. filed an 8-K report detailing the submission of matters to a vote of security holders, other events, and finan
NewAmsterdam Pharma Announces 2024 Annual General Meeting of Shareholders — DEF 14A · May 9, 2024 Risk: low
NewAmsterdam Pharma Co N.V. (NAMSW) filed a Proxy Statement (DEF 14A) with the SEC on May 9, 2024. The 2024 Annual General Meeting of Shareholders for NewAmster
NewAmsterdam Pharma Files 8-K on Financials — 8-K · May 9, 2024 Risk: low
NewAmsterdam Pharma Company N.V. filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition. The filing includes financial stat
NewAmsterdam Pharma Files Q1 2024 10-Q Report — 10-Q · May 8, 2024 Risk: low
NewAmsterdam Pharma Co N.V. (NAMSW) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Filed a 10-Q report for the period ending March 31, 2024. Repor
NewAmsterdam Pharma Reports Board & Officer Changes — 8-K · Apr 1, 2024 Risk: medium
On March 28, 2024, NewAmsterdam Pharma Co N.V. filed an 8-K report detailing changes in its board of directors and executive officers, including the appointment
NewAmsterdam Pharma Files 8-K — 8-K · Mar 4, 2024 Risk: low
NewAmsterdam Pharma Co N.V. filed an 8-K on March 4, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing pertains to th
Bain Capital Life Sciences Adjusts Stake in NewAmsterdam Pharma — SC 13D/A · Mar 1, 2024 Risk: medium
Bain Capital Life Sciences Fund II, L.P. and its affiliates have amended their Schedule 13D filing regarding NewAmsterdam Pharma Co N.V. The filing, dated March
NewAmsterdam Pharma Files 8-K on Financial Condition — 8-K · Feb 28, 2024 Risk: low
NewAmsterdam Pharma Company N.V. filed an 8-K on February 28, 2024, to report on its results of operations and financial condition. The filing indicates the com
NewAmsterdam Pharma Co N.V. Files 2023 Annual Report on Form 10-K — 10-K · Feb 28, 2024 Risk:
NewAmsterdam Pharma Co N.V. (NAMSW) filed a Annual Report (10-K) with the SEC on February 28, 2024. NewAmsterdam Pharma Co N.V. filed its 2023 annual report on
Frazier Life Sciences Affiliates Maintain Stake in NewAmsterdam Pharma — SC 13D/A · Feb 21, 2024 Risk: low
Frazier Life Sciences X, L.P. and its affiliates, including Frazier Life Sciences Public Fund, L.P. and Frazier Life Sciences XI, L.P., filed an SC 13D/A indica
NewAmsterdam Pharma Enters Material Definitive Agreement — 8-K · Feb 15, 2024 Risk: medium
NewAmsterdam Pharma Company N.V. filed an 8-K on February 15, 2024, reporting an event that occurred on February 13, 2024. The filing indicates an "Entry into a
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
NewAmsterdam Pharma Confirms Public Trading Registration — 8-K · Jan 22, 2024
NewAmsterdam Pharma Company N.V. filed an 8-K on January 22, 2024, primarily to disclose that its Ordinary Shares, with a nominal value of €0.12 per share, and
NewAmsterdam Pharma Reports Officer Comp, Director Changes — 8-K · Jan 8, 2024
NewAmsterdam Pharma Company N.V. filed an 8-K on January 8, 2024, reporting an event that occurred on January 4, 2024. This filing indicates a change in compens
NewAmsterdam Pharma Confirms Nasdaq Listing for Shares & Warrants — 8-K · Jan 4, 2024
NewAmsterdam Pharma Company N.V. filed an 8-K on January 4, 2024, to disclose that its Ordinary Shares, with a nominal value of €0.12 per share, are registered

Risk Profile

Risk Assessment: Of NAMSW's 39 recent filings, 2 were flagged as high-risk, 12 as medium-risk, and 25 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Newamsterdam Pharma CO N.V.'s most recent 10-Q filing (Nov 5, 2025):

Revenue: $0.348M
Net Income: -$72.005M
EPS: N/A
Debt-to-Equity: 0.08
Cash Position: $538.407M
Operating Margin: N/A
Total Assets: $786.427M
Total Debt: $58.357M

Key Executives

Albert Cha
Daniel Estes
Douglas Kling
Louise Kooij
Dr. Jane Osipov
Dr. Michael R. Rickles
William H. Lewis
Louis Lange, M.D., Ph.D.
Sander Slootweg
James N. Topper

Industry Context

The pharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on successful drug development and commercialization for revenue. The competitive landscape includes large established players and smaller biotech firms focused on niche areas. Recent trends include increased M&A activity and a focus on specialized therapies.

Top Tags

financial-reporting (8) · filing (7) · sec-filing (6) · financials (6) · corporate-governance (5) · regulation-fd (4) · 8-k (4) · 8-K (4) · 10-Q (4) · amendment (4)

Key Numbers

Net Loss (Q3 2025): $72.005M — Increased from $16.647M in Q3 2024
Revenue (Q3 2025): $0.348M — Decreased significantly from $29.111M in Q3 2024
Net Loss (YTD Q3 2025): $128.896M — Improved from $149.421M in YTD Q3 2024
Cash and Cash Equivalents: $538.407M — Decreased from $771.743M at Dec 31, 2024
Fair Value Change - Warrants (Q3 2025): $23.792M — Negative impact on Q3 net loss
R&D Expenses (YTD Q3 2025): $103.238M — Decreased from $116.511M in YTD Q3 2024
SG&A Expenses (YTD Q3 2025): $78.936M — Increased from $49.340M in YTD Q3 2024
Ordinary Shares Outstanding: 113,390,804 — As of October 31, 2025
Net Loss: $36.7M — Increased from $28.5M in Q2 2024, reflecting higher R&D.
R&D Expense: $30.1M — Up from $25.5M in Q2 2024, driven by obicetrapib clinical trials.
Cash & Equivalents: $250.3M — Decreased from $280.5M at year-end 2024, indicating cash burn.
Earnout Liability Decrease: $1.2M — Reflects updated probabilities of milestone achievement.
Public Warrants Gain: $0.8M — Gain from fair value adjustment during the quarter.
Reporting Period End Date: 2025-03-31 — Indicates the end of the fiscal quarter for which financial information is reported.
Filing Date: 2025-05-08 — The date the 10-Q was officially submitted to the SEC.

Related Companies

NAMS · MRNA · BNTX · PFE · NAP · NAPX · NAMP

Frequently Asked Questions

What are the latest SEC filings for Newamsterdam Pharma CO N.V. (NAMSW)?

Newamsterdam Pharma CO N.V. has 48 recent SEC filings from Jan 2024 to Nov 2025, including 30 8-K, 6 10-Q, 4 SC 13D/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of NAMSW filings?

Across 48 filings, the sentiment breakdown is: 2 bearish, 46 neutral. The dominant sentiment is neutral.

Where can I find Newamsterdam Pharma CO N.V. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Newamsterdam Pharma CO N.V. (NAMSW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Newamsterdam Pharma CO N.V.?

Key financial highlights from Newamsterdam Pharma CO N.V.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for NAMSW?

The investment thesis for NAMSW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Newamsterdam Pharma CO N.V.?

Key executives identified across Newamsterdam Pharma CO N.V.'s filings include Albert Cha, Daniel Estes, Douglas Kling, Louise Kooij, Dr. Jane Osipov and 5 others.

What are the main risk factors for Newamsterdam Pharma CO N.V. stock?

Of NAMSW's 39 assessed filings, 2 were flagged high-risk, 12 medium-risk, and 25 low-risk.

What are recent predictions and forward guidance from Newamsterdam Pharma CO N.V.?

Forward guidance and predictions for Newamsterdam Pharma CO N.V. are extracted from SEC filings as they are enriched.